The Clinic trials of Human Immunodeficiency Virus

Authors

  • Junhong Li

DOI:

https://doi.org/10.54097/hset.v8i.1207

Keywords:

HIV, Clinical, Diagnosis, Treatment.

Abstract

This review paper looks for future improvement for HIV. It is obvious that HIV has become a pandemic disease and causes serious problems to human life quality, social stability and public health. However, there are still a lot people get infected by HIV and the mortality of HIV patients has decreased compared with the time that the disease was discovered. By understanding the virus structure and the mechanisms when the pathogen enters the body, humans can find ways to solve AIDS infection in these ways, from the source of the pathogen, the transmission path, and patients infected by HIV. Second, by analyzing two successful cases of HIV cured patients and the failure cases, humans find out that not everybody is suitable for the same treatments as the two successful cased did. Although, nowadays, scientists are working on HIV vaccines, the process is very slow as there are still a lot of mysteries in human immunodeficiency virus and HIV vaccines. Few types of vaccines were undergoing clinical trials. Humans still have a long way to go to overcome HIV, but as more and more attention are paid to HIV patients and the projects which are trying to overcome it, HIV patients’ life quality had improved a lot and their life cycles are prolonged.

Downloads

Download data is not yet available.

References

Pneumocystis Pneumonia-Los Angeles. (1981, June 5). CDC.

Nyamweya, S., Hegedus, A., Jaye, A., Rowland-Jones, S., Flanagan, K. L., & Macallan, D. C. (2013). Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis. Reviews in medical virology, 23 (4), 221–240.

HIV/AIDS. (2021, November 30). WHO. https://www.who.int/data/gho/data/themes/hiv-aids

Opportunistic Infections. (2022, January 14). HIV.Gov. https://www.hiv.gov/hiv-basics/staying-in-hiv-care/other-related-health-issues/opportunistic-infections

Opportunistic Infections | Living with HIV | HIV Basics | HIV/AIDS | CDC. (2021, May 20). CDC. https://www.cdc.gov/hiv/basics/livingwithhiv/opportunisticinfections.html

Turner, B. G., & Summers, M. F. (1999). Structural biology of HIV. Journal of molecular biology, 285 (1), 1–32.

Margolis, A. M., Heverling, H., Pham, P. A., & Stolbach, A. (2014). A review of the toxicity of HIV medications. Journal of medical toxicology: official journal of the American College of Medical Toxicology, 10 (1), 26–39.

Jilg, N., & Li, J. Z. (2019). On the Road to a HIV Cure: Moving Beyond Berlin and London. Infectious disease clinics of North America, 33 (3), 857–868.

What Women Need to Know: The HIV Treatment Guidelines for Pregnant Women. (2009, August 11). Sn. Rutgers. Edu.

Brown T. R. (2015). I am the Berlin patient: a personal reflection. AIDS research and human retroviruses, 31 (1), 2–3.

Gupta, R. K., Abdul-Jawad, S., McCoy, L. E., Mok, H. P., Peppa, D., Salgado, M., Martinez-Picado, J., Nijhuis, M., Wensing, A., Lee, H., Grant, P., Nastouli, E., Lambert, J., Pace, M., Salasc, F., Monit, C., Innes, A. J., Muir, L., Waters, L., Frater, J., … Olavarria, E. (2019). HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature, 568 (7751), 244–248.

Sawinski D. (2014). The kidney effects of hematopoietic stem cell transplantation. Advances in chronic kidney disease, 21 (1), 96–105. https://doi.org/10.1053/j.ackd.2013.08.007

Broder, M. S., Quock, T. P., Chang, E., Reddy, S. R., Agarwal-Hashmi, R., Arai, S., & Villa, K. F. (2017). The Cost of Hematopoietic Stem-Cell Transplantation in the United States. American health & drug benefits, 10 (7), 366–374.

A Theoretical Approach To HIV Vaccine Development. (2019b, May 15). NIH: National Institute of Allergy and Infectious Diseases.

Downloads

Published

17-08-2022

How to Cite

Li, J. (2022). The Clinic trials of Human Immunodeficiency Virus. Highlights in Science, Engineering and Technology, 8, 523-528. https://doi.org/10.54097/hset.v8i.1207